- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04745559
Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy
February 21, 2024 updated by: H. Lee Moffitt Cancer Center and Research Institute
Optimizing Cellular and Humoral Immunity to Pneumococcus by Vaccination With Pneumococcal 13-valent Conjugate Vaccine Before and After CD19-targeted CAR T-cell Immunotherapy
The purpose of the study is to evaluate whether receiving the pneumococcal 13-valent conjugate vaccine (PCV13) before and after CD19-targeted CAR T cell therapy will optimize cellular and humoral immunity to pneumococcus.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
This is a phase II, single-institution study to investigate if pneumococcal vaccination before and after CD19-targeted CAR T cell therapy elicits cellular and humoral immunity to pneumococcus in patients with relapsed or refractory B cell lymphomas.
All the participants will receive the same treatment.
Immunoglobulins (IgG) against pneumococcal serotypes not included in the vaccine will be served as an internal control.
Treatment includes the same dose (0.5ml) of PCV13 one time prior to apheresis followed by two times after CAR T cell therapy
Study Type
Interventional
Enrollment (Estimated)
26
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Ashley O'Neil
- Phone Number: 813-745-5240
- Email: ashley.oneil@moffitt.org
Study Locations
-
-
Florida
-
Tampa, Florida, United States, 33612
- Recruiting
- Moffitt Cancer Center
-
Contact:
- Ashley O'Neil
- Phone Number: 813-745-5240
- Email: ashley.oneil@moffitt.org
-
Sub-Investigator:
- Marco Davila, MD, PhD
-
Sub-Investigator:
- Michael Jain, MD, PhD
-
Sub-Investigator:
- Farhad Khimani, MD
-
Sub-Investigator:
- Javier Pinilla, MD, PhD
-
Sub-Investigator:
- Julio C Chavez, MD, MS
-
Sub-Investigator:
- Aleksandr Lazaryan, MD, PhD, MPH
-
Sub-Investigator:
- Dasom Lee, MD
-
Sub-Investigator:
- Bijal D Shah, MD, MS
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- In good health as evidenced by medical history or diagnosed with relapsed or chemotherapy-refractory diffuse large B cell lymphoma (DLBCL), primary mediastinal B cell lymphoma (PMLBCL), transformed follicular lymphoma (TFL) high-grade B cell lymphoma (HGBCL) or Follicular Lymphoma. Patients must be under consideration for treatment with any CD19-targeted CAR T cell therapy, per institutional standards. Patients undergoing active vital organ testing with a planned apheresis date for CAR T cell therapy may be considered eligible.
- Signed informed consent form in accordance with institutional and federal law policies
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Male or female, age over 18
- For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation
Exclusion Criteria:
- Pregnant or lactating woman, as evaluated by serum testing within 2 weeks of administration of the first vaccine. Only women of childbearing potential will undergo serum/urine pregnancy testing. A woman will be considered of childbearing potential unless she is status-post hysterectomy or tubal ligation or without menstrual periods in the preceding 12 months.
- Common variable immunodeficiency or other inherited systemic immunodeficiency syndrome
- History of severe allergy (e.g., anaphylaxis) to any component of pneumococcal conjugate vaccine 7 valent (PCV7), PCV13, or any diphtheria-toxoid containing vaccine.
- Inclusion on a separate trial in which patients may be randomized or otherwise started on maintenance chemotherapies within the first 3 months of CD19-targeted CAR T cell therapy
- Patients with significant psychiatric illness likely to affect compliance, as determined by the treating physician
- Active or uncontrolled infections
- Platelet count <10,000 cells/microliter
- Lymphocyte count <200 cells/microliter
- Intervenous immunoglobulin (IVIG) administration within one month of planned apheresis for collection for CD19-targeted CAR T cell manufacture
- History of PCV13 administration within one month of planned apheresis for collection for CD19-targeted CAR T cell manufacture
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment
Pneumococcal conjugate vaccine (PCV13) .5 ml will be administered intramuscularly three times: 7 days (range 4 to 21 days) before apheresis collection and on day +30 (range +21 to +37) and day +90 (range +75 to +115) after CAR T cell infusion.
|
Licensed heptavalent pneumococcal conjugate vaccine (PCV13, Pneumococcal 13-valent conjugate vaccine
Other Names:
This is a personalized therapeutic approach that entails removal of T cells from patient's peripheral blood, genetic modification, activation and expansion in vitro to retarget cells against CD19 protein on the surface of B cells, and infusion of the genetically engineered cells back into the patient.
CD19 is a surface protein that is expressed on B cells starting from early pre-B cells to mature fully differentiated B cells.
Therefore, CD19-targeted CAR T cell therapy can effectively treat refractory B cell lymphomas.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Humoral Response Rate -PCV13 vaccine
Time Frame: 90 days post CAR T therapy
|
Humoral sero-protection rate elicited by the PCV13 vaccine intervention as measured on day+90 post CART
|
90 days post CAR T therapy
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Increase in PCV13 specific serotype IgG levels
Time Frame: 90 days post CAR T therapy
|
PCV13 specific serotype IgG levels on day +90 post CAR T cell therapy as an absolute and as a change from baseline
|
90 days post CAR T therapy
|
Increase in On-Specific Serotype IgG levels
Time Frame: 90 days post CAR T therapy
|
Non-specific serotype IgG levels on day +90 post CAR T cell therapy as an absolute and as a change from baseline
|
90 days post CAR T therapy
|
Response Rate of CD19-targeted CAR T therapy when combined with PCV13 vaccination
Time Frame: 90 days post CAR T therapy
|
Percentage of patients whose cancer shrinks or disappears after treatment
|
90 days post CAR T therapy
|
Progression Free Survival
Time Frame: at 90 days and 180 days post CAR T therapy
|
Progression Free Survival (PFS) from start of treatment to death of any cause, disease progression or relapse of the date of last follow-up, whichever comes first.
|
at 90 days and 180 days post CAR T therapy
|
Overall Survival
Time Frame: 180 days post CAR T therapy
|
Overall Survival (OS):The length of time from the start of treatment until death by any cause
|
180 days post CAR T therapy
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Frederick Locke, MD, Moffitt Cancer Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 18, 2021
Primary Completion (Estimated)
May 1, 2024
Study Completion (Estimated)
May 1, 2025
Study Registration Dates
First Submitted
February 4, 2021
First Submitted That Met QC Criteria
February 4, 2021
First Posted (Actual)
February 9, 2021
Study Record Updates
Last Update Posted (Estimated)
February 22, 2024
Last Update Submitted That Met QC Criteria
February 21, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma, Non-Hodgkin
- Lymphoma
- Lymphoma, Follicular
- Lymphoma, B-Cell
- Lymphoma, Large B-Cell, Diffuse
- Physiological Effects of Drugs
- Immunologic Factors
- Heptavalent Pneumococcal Conjugate Vaccine
Other Study ID Numbers
- MCC-20571
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Follicular Lymphoma
-
Joseph TuscanoNational Cancer Institute (NCI); Genentech, Inc.; Pharmacyclics LLC.RecruitingAnn Arbor Stage II Follicular Lymphoma | Ann Arbor Stage III Follicular Lymphoma | Ann Arbor Stage IV Follicular Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular LymphomaUnited States
-
National Cancer Institute (NCI)TerminatedStage III Grade 1 Follicular Lymphoma | Stage III Grade 2 Follicular Lymphoma | Stage III Grade 3 Follicular Lymphoma | Stage IV Grade 1 Follicular Lymphoma | Stage IV Grade 2 Follicular Lymphoma | Stage IV Grade 3 Follicular LymphomaUnited States
-
National Cancer Institute (NCI)RecruitingRecurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular LymphomaUnited States
-
Memorial Sloan Kettering Cancer CenterFox Chase Cancer Center; Pharmacyclics LLC.TerminatedFollicular Lymphoma | Follicular Lymphoma, Grade 1 | Follicular Lymphoma, Grade 2 | Follicular Lymphoma Grade IIIaUnited States
-
Olivia Newton-John Cancer Research InstituteBristol-Myers Squibb; Barwon Health; Austin Health; Eastern Health; Fiona Stanley... and other collaboratorsRecruitingFollicular Lymphoma Stage II | Follicular Lymphoma Stage III | Follicular Lymphoma Stage IVAustralia
-
Robert LowskyNational Cancer Institute (NCI); Janssen, LP; The Leukemia and Lymphoma Society; Rising Tide FoundationCompletedMantle Cell Lymphoma | Marginal Zone Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular LymphomaUnited States
-
Massachusetts General HospitalTG TherapeuticsActive, not recruitingLymphoma | Follicular Lymphoma | Marginal Zone Lymphoma | Follicular Lymphoma, Grade 1 | Follicular Lymphoma Grade IIIa | Marginal Zone B Cell Lymphoma | Follicular Lymphoma Grade 2United States
-
Fondazione Italiana Linfomi ONLUSCompletedFollicular Lymphoma, Grade 1 | Follicular Lymphoma, Grade 2 | Follicular Lymphoma Grade 3AItaly
-
National Cancer Institute (NCI)Celgene CorporationActive, not recruitingAnn Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma | Ann Arbor Stage II Grade 3 Non-Contiguous... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingGrade 3a Follicular Lymphoma | Ann Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann Arbor Stage III Grade 3 Follicular Lymphoma | Ann Arbor Stage...United States
Clinical Trials on Pneumococcal conjugate vaccine (PCV13)
-
University of Witwatersrand, South AfricaUniversity College, LondonCompleted
-
Sinovac Life Sciences Co., Ltd.RecruitingPneumococcal InfectionsChina
-
University of OxfordUniversity of Southampton; University of Bristol; University of LondonCompleted
-
Aghia Sophia Children's Hospital of AthensUnknownImmunogenicity, Vaccine | Immunologic MemoryGreece
-
University of OxfordCompletedType 1 Diabetes MellitusUnited Kingdom
-
University of California, Los AngelesActive, not recruitingInfection in Solid Organ Transplant RecipientsUnited States
-
Telethon Kids InstitutePapua New Guinea Institute of Medical ResearchCompleted
-
Murdoch Childrens Research InstituteNational Health and Medical Research Council, Australia; GlaxoSmithKline; Bill... and other collaboratorsCompleted
-
London School of Hygiene and Tropical MedicineUniversity College, London; Bill and Melinda Gates Foundation; Wellcome Trust; KEMRI-Wellcome... and other collaboratorsActive, not recruitingPneumococcal Infection | Streptococcus Pneumoniae Infection | Invasive Pneumococcal Disease, Protection AgainstKenya
-
St. Antonius HospitalCompletedPneumonia | Immune Response | Streptococcus PneumoniaeNetherlands